Michael Osayamen, MD
Cardiovascular Disease · Jackson, TNNPI 1346218070
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,462 of the $8,746 with a category attached, or 73.9%. It is spread thinly across 25 manufacturers, the largest accounting for just 20.7%.
Across 215 payments — averaging $40.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$2K
- Medtronic$1K
- Abbott$879
- AstraZeneca$802
- E.r. Squibb & Sons, L.L.C.$561
- Novartis$535
- plus $3K from 19 others
Across 24 payments — averaging $11,299 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Siemens Medical Solutions USA, Inc.$149K
- AstraZeneca$69K
- Amgen$31K
- Ionis Pharmaceuticals, Inc.$13K
- Novartis$10K
What the payments were for
- Travel & lodging$1,59818%
- Food & beverage$6,46274%
- Education$6868%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 6 | $1,807 |
| Medtronic(2 entities) | 18 | $1,120 |
| Abbott | 11 | $879 |
| AstraZeneca | 11 | $802 |
| E.r. Squibb & Sons, L.L.C. | 24 | $561 |
| Novartis | 46 | $535 |
| Amgen | 16 | $472 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 30 | $466 |
| Bard Peripheral Vascular, Inc. | 7 | $428 |
| Pfizer | 19 | $380 |
| Abiomed | 5 | $295 |
| Alnylam Pharmaceuticals Inc. | 3 | $294 |
| Cook Medical LLC | 3 | $275 |
| United Therapeutics Corporation | 1 | $107 |
| Merck | 1 | $96 |
| Bayer | 3 | $46 |
| Novo Nordisk | 2 | $42 |
| Boehringer Ingelheim | 2 | $28 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Cardiovascular Systems Inc. | 1 | $19 |
| Boston Scientific | 1 | $18 |
| G Medical Diagnostic Services, Inc. | 1 | $15 |
| GSK | 1 | $14 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
| Venclose Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$466
- TurboHawk$439
- Repatha$344
- AMVUTTRA$275
- Diamondback Peripheral$246
- CARDIOMEMS$238
- Cook Medical Lead Management - Lead Extraction$188
- MitraClip$152
- Impella$123
- HeartMate 3 Left Ventricular Dev$121
- LOKELMA$120
- Micra$108
- TYVASO$107
- VYNDAQEL$102
- CAMZYOS$102
- COBALT DR MRI SURESCAN$102
How this compares
$8,746 in reported general payments places this provider in the 80th percentile of 429 cardiovascular disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 434 | $355,998 |
| EntrestoSacubitril/Valsartan | 69 | $72,929 |
| FarxigaDapagliflozin Propanediol | 86 | $53,429 |
| XareltoRivaroxaban | 58 | $42,450 |
| JardianceEmpagliflozin | 52 | $40,322 |
| Repatha SureclickEvolocumab | 26 | $37,959 |
| Ranolazine ErRanolazine | 107 | $13,287 |
| Repatha SyringeEvolocumab | 19 | $9,972 |
| Metoprolol Succinate | 249 | $3,013 |
| Digoxin | 145 | $2,831 |
| Rosuvastatin Calcium | 275 | $2,813 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 214 | $2,564 |
| PradaxaDabigatran Etexilate Mesylate | 12 | $2,286 |
| Carvedilol | 308 | $2,109 |
| Amiodarone Hcl | 89 | $2,078 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $380 | $355,998434 claims |
| NovartisEntresto | $535 | $72,92969 claims |
| AstraZenecaFarxiga | $802 | $53,42986 claims |
| Boehringer IngelheimJardiance, Pradaxa | $28 | $42,60864 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 429 cardiovascular disease providers in Tennessee.
Other cardiovascular disease in Jackson
- Adeyinka AgbetoyinJackson$112K
- Elliot KurbanJackson$68K
- Shahzad ShahJackson$15K
- Mohsin AlhaddadJackson$14K
- Alexander AlperovichJackson$13K
- Nirav PatelJackson$12K
- David MetzgerKingsport$555K
- Christopher EllisNashville$527K
- Joann LindenfeldNashville$270K
- Steven GubinMemphis$248K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.